Compare Stocks: AQB, BCTX, GNTA, and NXTC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQB AquaBounty Technologies	$1.31	$1.08	$0.74 ▼ $2.95	$6.74M	1.39	1.47 million shs	51,331 shs
BCTX Briacell Therap	$3.46 -15.0%	$3.45	$2.60 ▼ $14.68	$35.41M	1.14	116,822 shs	8.70 million shs
GNTA Genenta Science	$1.15 -8.7%	$1.52	$0.55 ▼ $10.00	$29.73M	0.77	49,951 shs	43,082 shs
NXTC NextCure	$5.89 -6.4%	$4.32	$1.55 ▼ $15.74	$22.72M	1.26	399,032 shs	121,630 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQB AquaBounty Technologies	0.00%	-6.43%	+43.96%	+33.69%	+74.67%
BCTX Briacell Therap	-14.99%	+2.06%	-3.35%	+1.17%	-50.42%
GNTA Genenta Science	-8.73%	-8.73%	-27.67%	+92.50%	-67.24%
NXTC NextCure	-6.36%	-23.61%	+38.92%	-16.10%	+14.81%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQB AquaBounty Technologies	$1.31	$1.08	$0.74 ▼ $2.95	$6.74M	1.39	1.47 million shs	51,331 shs
BCTX Briacell Therap	$3.46 -15.0%	$3.45	$2.60 ▼ $14.68	$35.41M	1.14	116,822 shs	8.70 million shs
GNTA Genenta Science	$1.15 -8.7%	$1.52	$0.55 ▼ $10.00	$29.73M	0.77	49,951 shs	43,082 shs
NXTC NextCure	$5.89 -6.4%	$4.32	$1.55 ▼ $15.74	$22.72M	1.26	399,032 shs	121,630 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQB AquaBounty Technologies	0.00%	-6.43%	+43.96%	+33.69%	+74.67%
BCTX Briacell Therap	-14.99%	+2.06%	-3.35%	+1.17%	-50.42%
GNTA Genenta Science	-8.73%	-8.73%	-27.67%	+92.50%	-67.24%
NXTC NextCure	-6.36%	-23.61%	+38.92%	-16.10%	+14.81%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AQB AquaBounty Technologies	1.00	Sell	N/A	N/A
BCTX Briacell Therap	1.00	Sell	N/A	N/A
GNTA Genenta Science	1.00	Sell	N/A	N/A
NXTC NextCure	2.25	Hold	$19.00	222.58% Upside

Current Analyst Ratings Breakdown

Latest AQB, BCTX, GNTA, and NXTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/17/2026	GNTA Genenta Science	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	NXTC NextCure	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/12/2026	AQB AquaBounty Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/12/2026	NXTC NextCure	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/30/2026	GNTA Genenta Science	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	BCTX Briacell Therap	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/15/2026	NXTC NextCure	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
7/10/2026	GNTA Genenta Science	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/8/2026	AQB AquaBounty Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/7/2026	NXTC NextCure	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/24/2026	GNTA Genenta Science	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 8/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AQB AquaBounty Technologies	$2.47M	2.73	N/A	N/A	($0.49) per share	-2.67
BCTX Briacell Therap	N/A	N/A	N/A	N/A	$9.20 per share	N/A
GNTA Genenta Science	N/A	N/A	N/A	N/A	$1.29 per share	N/A
NXTC NextCure	N/A	N/A	N/A	N/A	$9.97 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AQB AquaBounty Technologies	-$18.49M	-$0.82	N/A	N/A	N/A	N/A	-147.07%	-28.73%	11/10/2026 (Estimated)
BCTX Briacell Therap	-$26.31M	-$7.92	N/A	N/A	N/A	N/A	-153.53%	-129.26%	N/A
GNTA Genenta Science	-$7.39M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/2/2026 (Estimated)
NXTC NextCure	-$55.84M	-$8.70	N/A	N/A	N/A	N/A	-154.62%	-100.19%	11/4/2026 (Estimated)

Latest AQB, BCTX, GNTA, and NXTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/2/2026	N/A	GNTA Genenta Science	-$0.2741	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	AQB AquaBounty Technologies	N/A	-$0.26	N/A	-$0.32	N/A	N/A
8/6/2026	Q2 2026	NXTC NextCure	-$1.95	-$2.80	-$0.85	-$2.80	N/A	N/A
6/9/2026	Q3 2026	BCTX Briacell Therap	N/A	-$0.99	N/A	-$0.99	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AQB AquaBounty Technologies	N/A	N/A	N/A	N/A	N/A
BCTX Briacell Therap	N/A	N/A	N/A	N/A	N/A
GNTA Genenta Science	N/A	N/A	N/A	N/A	N/A
NXTC NextCure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AQB AquaBounty Technologies	N/A	4.26	4.26
BCTX Briacell Therap	N/A	7.07	7.07
GNTA Genenta Science	0.35	14.16	14.16
NXTC NextCure	N/A	3.47	3.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AQB AquaBounty Technologies	8.92%
BCTX Briacell Therap	15.42%
GNTA Genenta Science	15.13%
NXTC NextCure	42.65%

Insider Ownership

Company	Insider Ownership
AQB AquaBounty Technologies	1.02%
BCTX Briacell Therap	0.74%
GNTA Genenta Science	28.99%
NXTC NextCure	11.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AQB AquaBounty Technologies	100	5.15 million	5.10 million	No Data
BCTX Briacell Therap	8	8.70 million	8.64 million	No Data
GNTA Genenta Science	7	23.59 million	16.75 million	Not Optionable
NXTC NextCure	90	3.61 million	3.18 million	No Data

AQB, BCTX, GNTA, and NXTC Headlines

Recent News About These Companies

Research Analysts Issue Forecasts for NextCure Q3 Earnings

August 16, 2026 | americanbankingnews.com

Wall Street Zen Upgrades NextCure (NASDAQ:NXTC) to "Hold"

August 15, 2026 | americanbankingnews.com

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001

August 10, 2026 | prnewswire.com

NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results

August 6, 2026 | markets.businessinsider.com

NextCure (NASDAQ:NXTC) Major Shareholder Adar1 Capital Management, Llc Purchases 36,303 Shares of Stock

August 4, 2026 | insidertrades.com

Insider Buying: NextCure (NASDAQ:NXTC) Major Shareholder Acquires $17,050.00 in Stock

July 30, 2026 | insidertrades.com

The M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—VEEE, NXTC, TCBK, and FHB

July 23, 2026 | globenewswire.com

Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for ...

July 21, 2026 | caledonianrecord.comC

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—VEEE, NXTC, TCBX, and FHB

July 21, 2026 | globenewswire.com

Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for Public Shareholders

July 21, 2026 | globenewswire.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of NextCure, Inc. (NASDAQ: NXTC)

July 14, 2026 | prnewswire.com

New biotech Avere plots listing via NextCure merger

July 14, 2026 | pharmaphorum.comP

NXTC Stock Alert: Halper Sadeh LLC is Investigating Whether NextCure, Inc. is Obtaining a Fair Price for its Shareholders

July 14, 2026 | aol.comA

NextCure (NXTC) Stock Skyrockets 300% Following $320 Million Avere Therapeutics Merger Agreement

July 14, 2026 | blockonomi.com

NextCure announces reverse merger with privately held Avere

July 14, 2026 | seekingalpha.com

Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for Public Shareholders

July 14, 2026 | prnewswire.com

NextCure skyrockets on Avere reverse-merger deal and $320 million financing plan

July 14, 2026 | quiverquant.comQ

NextCure and Avere Therapeutics Announce Definitive Merger and $320 Million Financing to Advance Oral IL-23 Therapy AVR-001

July 14, 2026 | quiverquant.comQ

NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy

July 14, 2026 | globenewswire.com

3 Cancer Stocks to Watch as Oncology Innovation Accelerates

July 8, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQB, BCTX, GNTA, and NXTC Company Descriptions

AquaBounty Technologies NASDAQ:AQB

$1.31 0.00 (0.00%)

As of 08/24/2026 04:00 PM Eastern

AquaBounty Technologies, Inc., a biotechnology company, operates in the aquaculture industry in the United States and Canada. The company engages in genetic, genomic, and fish health and nutrition research activities. It also operates salmon farms using proprietary technology. In addition, the company offers AquAdvantage Salmon, a genetically engineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts. The company was formerly known as Aqua Bounty Farms, Inc. and changed its name to AquaBounty Technologies, Inc. in June 2004. AquaBounty Technologies, Inc. was incorporated in 1991 and is headquartered in Harvard, Massachusetts.

Briacell Therap NASDAQ:BCTX

$3.46 -0.61 (-14.99%)

Closing price 08/24/2026 04:00 PM Eastern

Extended Trading

$3.61 +0.15 (+4.31%)

As of 08:32 AM Eastern

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Genenta Science NASDAQ:GNTA

$1.15 -0.11 (-8.73%)

Closing price 08/24/2026 04:00 PM Eastern

Extended Trading

$1.12 -0.02 (-2.17%)

As of 08:33 AM Eastern

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

NextCure NASDAQ:NXTC

$5.89 -0.40 (-6.36%)

Closing price 08/24/2026 04:00 PM Eastern

Extended Trading

$5.94 +0.05 (+0.85%)

As of 08:31 AM Eastern

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AQB, BCTX, GNTA, and NXTC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AQB, BCTX, GNTA, and NXTC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AQB, BCTX, GNTA, and NXTC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQB, BCTX, GNTA, and NXTC Company Descriptions

AquaBounty Technologies NASDAQ:AQB

Briacell Therap NASDAQ:BCTX

Genenta Science NASDAQ:GNTA

NextCure NASDAQ:NXTC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AQB, BCTX, GNTA, and NXTC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AQB, BCTX, GNTA, and NXTC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AQB, BCTX, GNTA, and NXTC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQB, BCTX, GNTA, and NXTC Company Descriptions

AquaBounty Technologies NASDAQ:AQB

Briacell Therap NASDAQ:BCTX

Genenta Science NASDAQ:GNTA

NextCure NASDAQ:NXTC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools